The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 369 | 481 | 434 | 283 |
| Depreciation and amortization | 239 | 260 | 248 | 250 |
| Impairment of goodwill | - | 0 | 0 | 0 |
| Impairment of long-lived assets and assets held for sale | 10 | 773 | 78 | 100 |
| Net change in operating assets and liabilities | 617 | -229 | 560 | 335 |
| Deferred income taxes net and uncertain tax positions | -22 | -595 | 107 | -211 |
| Stock-based compensation | 43 | 51 | 34 | 38 |
| Other items | -54 | -41 | 28 | 102 |
| Net loss (gain) from sale of business and long-lived assets | 8 | 0 | 0 | 0 |
| Net cash provided by (used in) operating activities | -40 | 1,158 | 369 | 227 |
| Beneficial interest collected in exchange for securitized accounts receivables | 354 | 282 | 274 | 336 |
| Purchases of property, plant and equipment and intangible assets | 168 | 142 | 136 | 96 |
| Proceeds from sale of businesses and long-lived assets, net | 42 | 0 | 8 | 9 |
| Proceeds from sale of investments | - | 42 | 0 | - |
| Acquisitions of businesses, net of cash acquired | - | 0 | 0 | 0 |
| Purchases of investments and other assets | 0 | 17 | 13 | 16 |
| Other investing activities | -1 | 0 | -2 | -3 |
| Net cash provided by (used in) investing activities | 229 | 165 | 135 | 236 |
| Repayment of senior notes and loans and other long term liabilities | - | 0 | 444 | 2,300 |
| Proceeds from senior notes, net of issuance costs | - | -7 | - | 2,305 |
| Proceeds from short term debt | - | 0 | - | - |
| Repayment of senior notes and loans and other long-term liabilities | 0 | - | - | - |
| Proceeds from senior notes, net of issuance costs | - | - | 2,298 | - |
| Repayment of short term debt | - | 0 | - | - |
| Repayment of convertible debentures | 23 | - | - | - |
| Purchase of shares from redeemable and non-redeemable non-controlling interests | 0 | 0 | 0 | 0 |
| Dividends paid to redeemable and non-redeemable non-controlling interests | 0 | 0 | 0 | 0 |
| Other financing activities | 36 | 40 | -2 | 0 |
| Net cash provided by (used in) financing activities | 13 | 40 | -453 | 6 |
| Effect of exchange rate changes on cash and cash equivalents | -17 | -10 | -9 | -5 |
| Net change in cash and cash equivalents | 185 | 1,353 | 42 | 464 |
| Balance of cash and cash equivalents at beginning of period | 3,556 | 2,203 | 2,161 | 1,697 |
| Balance of cash and cash equivalents at end of period | 3,741 | 3,556 | 2,203 | 2,161 |
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)